Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2029

Conditions

Colorectal CancerRegorafenibHigh Risk Patients

Interventions

DRUG

Regorafenib (CT)

Given by po

DRUG

Lorigerlimab

Given by IV

Trial Locations (1)

MD Anderson Cancer Center, Houston